MBX Biosciences, Inc.
MBX evidence brief
What we can confirm
- BioSniper Score:
- 5.7 / 10
- Market Cap:
- $3.03B
What it means
What to watch
Prepared research question
What matters most for MBX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MBX
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, with lead programs in hypoparathyroidism and obesity.
Key risk: Clinical trial uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$3.03B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials for MBX Biosciences, Inc..
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, with lead programs in hypoparathyroidism and obesity.
- Cash & equivalents of $54.1M as of 2026-06-30 [sec].
- Net income of -$37.1M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $409.5M as of 2026-06-30 [sec].
- Lead candidate canvuparatide (once-weekly PTH replacement for hypoparathyroidism) is entering a Phase 3 trial in Q3 2026 [sec_mda · as of 2026-08-06].
- Obesity candidate MBX 4291 (GLP-1/GIP co-agonist prodrug) is in Phase 1; 12-week MAD Part C data expected Q4 2026 [sec · filed 2026-08-06].
What works
- Proprietary PEP™ platform designed to extend time-action profiles and reduce peak-to-trough ratios, potentially improving patient outcomes [sec_mda · as of 2026-08-06].
- Canvuparatide one-year data showed sustained benefit, supporting a Phase 3 start in Q3 2026 [news · published 2026-08-06].
- MBX 4291 initial Phase 1 data support potential once-monthly dosing with no serious adverse events [sec · filed 2026-05-11].
- Expanding obesity pipeline with nomination of MBX 5765 (amycretin prodrug) and MBX 6180 (GLP-1/GIP/GCG triple agonist) [sec · filed 2026-05-11; news · published 2026-08-06].
What to weigh
- Accumulated deficit of $285.1M as of 2026-06-30, with expenses expected to increase substantially [sec_mda · as of 2026-08-06].
- Net loss of $37.1M for the six months ended 2026-06-30 [sec].
- Company discontinued investment in a Phase 2b trial for imapextide in PBH, indicating pipeline prioritization risks [sec · filed 2026-05-11].
- Forward-looking statements caution that clinical data may differ from interim results and regulatory approvals are uncertain [sec · filed 2026-08-27].
From the filings
Quoted directly from source documents.
Phase 3 plan for canvuparatide
“We plan to initiate a Phase 3 clinical trial of canvuparatide in the third quarter of 2026”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial uncertainty — Differences between interim and final data could affect program timelines and outcomes [sec · filed 2026-08-27].
- Regulatory approval risk — Ability to obtain regulatory approvals on expected timelines is uncertain [sec · filed 2026-08-27].
- Increasing operating losses — Expenses expected to increase substantially as pipeline advances, widening accumulated deficit [sec_mda · as of 2026-08-06].
- Dependence on third parties — Reliance on contract manufacturers and other third parties for development and manufacturing [sec · filed 2026-08-06].
What to watch
- Initiation of Phase 3 trial for canvuparatide in Q3 2026 [sec_mda · as of 2026-08-06].
- Data from 12-week MAD Part C of MBX 4291 expected Q4 2026 [sec · filed 2026-08-06].
- Progress of obesity pipeline candidates MBX 5765 and MBX 6180 [sec · filed 2026-05-11; news · published 2026-08-06].
- Cash runway and expense trajectory given increasing operating losses [sec_mda · as of 2026-08-06].
Sources: News · SEC filings · SEC MD&A · Generated October 3, 2026 · How we verify sources →
Run MBX Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MBX Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.06 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 5 sells (180d)
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 11.2%
- Days to cover
- 8.0
- Shares short
- 3,786,542
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MBX short interestGovernance
Frequently asked questions
What is the AI investment thesis for MBX Biosciences, Inc.?
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, with lead programs in hypoparathyroidism and obesity.
Who is the CEO of MBX Biosciences, Inc.?
Mr. Steven L. Hoerter is the chief executive officer of MBX Biosciences, Inc. (MBX).
Where is MBX Biosciences, Inc. headquartered?
MBX Biosciences, Inc. (MBX) is headquartered in Carmel, IN, United States.
What therapeutic areas does MBX Biosciences, Inc. focus on?
MBX Biosciences, Inc. develops therapies across Oncology, Metabolic, Dermatology, Nephrology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.